Global Information
회사소개 | 문의

미국의 당뇨병 모니터링, 치료, 약물 전달 시장 처치 건수

US Procedure Numbers for Diabetes Monitoring, Treatment and Drug Delivery 2017 - MedPro

리서치사 iData Research Inc.
발행일 2016년 11월 상품 코드 392572
페이지 정보 영문 40 Pages
가격
US $ 1,995 ₩ 2,290,200 PDF by E-mail (Single User License) help
1명만 이용할 수 있는 라이선스입니다. DRM(디지털 저작권 관리시스템)장착 PDF파일로 Copy & Paste 는 가능하지만, 편집은 할 수 없습니다. 인쇄는 불가능합니다.
US $ 2,394 ₩ 2,748,300 PDF by E-mail (Site License) help
동일 사업장 내에서 공유하여 이용할 수 있는 라이선스입니다. DRM(디지털 저작권 관리시스템)장착 PDF파일로 Copy & Paste 는 가능하지만, 편집은 할 수 없습니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 2,992 ₩ 3,434,800 PDF by E-mail (Corporate License) help
동일 기업의 모든 분이 이용할 수 있는 글로벌 라이선스입니다. 이용 인원수에 제한은 없습니다. DRM(디지털 저작권 관리시스템)장착 PDF파일로 Copy & Paste 는 가능하지만, 편집은 할 수 없습니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.

주의 : 본 보고서는 DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로, 라이선스에 따라 자료 이용 및 인쇄 등에 제약이 있을 수 있습니다. 자세한 내용은 라이선스 설명문( )을 참고하여 주시기 바랍니다.



미국의 당뇨병 모니터링, 치료, 약물 전달 시장 처치 건수 US Procedure Numbers for Diabetes Monitoring, Treatment and Drug Delivery 2017 - MedPro
발행일: 2016년 11월 페이지 정보 : 영문 40 Pages

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

한글목차

미국의 당뇨병 모니터링, 치료, 약물 전달 시장은 2016년에 확대될 전망이며, 앞으로도 성장이 지속될 것으로 예측됩니다.

미국의 당뇨병 모니터링, 치료, 약물 전달( Diabetes Monitoring, Treatment and Drug Delivery) 시장을 조사 분석했으며, 처치 개요, 처치 건수, 예측 등의 정보를 전해드립니다.

제1장 조사 방법

제2장 질환 개요

  • 서론
    • 당뇨병의 종류
    • 당뇨병의 합병증
    • 1형·2형 당뇨병 관련 위험인자
    • 징후와 증상
    • 당뇨병 모니터링
    • 치료
    • 약물 전달 시스템

제3장 시술

  • 시술 개요

약어

LSH 16.12.02

영문목차

The full report suite on the U.S. market for diabetes monitoring, treatment and drug delivery includes blood glucose meters, blood glucose test strips, lancets and lancing devices, continuous glucose monitoring (CGM), insulin, inulin pens, insulin syringes and insulin pumps. Sanofi and Novo Nordisk recently launched next-generation insulin products: insulin glargine U-300 (Toujeo®) and insulin degludec (Tresiba®), respectively. Both of these insulin analogs are "ultra-long-acting" and have an average duration of 24 to 36 hours, which means that patients will only be required to perform once-daily injections. Novo Nordisk is currently developing Ryzodeg®, a premixed insulin analog comprising insulin degludec (Tresiba®) and insulin aspart (NovoLog®), in addition to an "ultra-rapid-acting" insulin analog, which are both expected to be launched during the forecast period. The insulin-dependent patient population is expected to transition to next-generation insulin products and will contribute to the growth of the insulin market and associated insulin delivery markets.

Segments Covered in this Procedure Volume Research

This market study focuses specifically on the volume of procedures. It includes analysis of procedures.

This data outlines the exact growth rates for procedures. If you're interested in seeing the trends in procedures to formulate your market sizing and forecasts this is the most accurate and most affordable way to do it.

About Procedure Volume Research (MedPro)

Our analysts meticulously research for 3 to 4 months to put together a suite of reports, which is a comprehensive analysis on a group of healthcare markets. A MedPro is one portion of that analysis that outlines only the procedure volumes and forecasts for each market in that suite of reports.

This procedural analysis is incorporated in our market size analysis and forecasting which are available when purchasing a MedSuite, MedView or MedCore.

Where Do We Get Our Procedure Data?

Our team of analysts has proprietary data that we've been collecting for over a decade as well as government and private databases like that from CMS and hospital records. By looking at multiple sources we are able to triangulate on orthopedic soft tissue procedure volumes that influence and coincide with our overall market sizing.

Questions This Report will Help You Answer:

What is affecting the volume of procedures?

How many procedures were done in 2016?

How many procedures were done historically?

How many procedures can we expect in 2023 and what is the growth trend?

TABLE OF CONTENTS I

LIST OF FIGURES III

LIST OF CHARTS IV

EXECUTIVE SUMMARY 1

U.S. DIABETES MONITORING, TREATMENT AND DRUG DELIVERY MARKET OVERVIEW 1

COMPETITIVE ANALYSIS 4

MARKET TRENDS 7

MARKET DEVELOPMENTS 9

PROCEDURE NUMBERS 10

PROCEDURE CODES INVESTIGATED 10

MARKETS INCLUDED 11

KEY REPORT UPDATES 13

VERSION HISTORY 13

RESEARCH METHODOLOGY 14

  • 1.1 RESEARCH SCOPE 14
  • 1.2 IDATA'S 9-STEP METHODOLOGY 14
    • Step 1: Project Initiation & Team Selection 14
    • Step 2: Prepare Data Systems and Perform Secondary Research 16
    • Step 3: Preparation for Interviews & Questionnaire Design 17
    • Step 4: Performing Primary Research 18
    • Step 5: Research Analysis: Establishing Baseline Estimates 20
    • Step 6: Market Forecast and Analysis 21
    • Step 7: Identify Strategic Opportunities 23
    • Step 8: Final Review and Market Release 24
    • Step 9: Customer Feedback and Market Monitoring 25

DISEASE OVERVIEW 26

  • 2.1 INTRODUCTION 26
    • 2.1.1 Types of Diabetes 26
    • 2.1.2 Diabetes Complications 28
    • 2.1.3 Risk Factors Associated with Type 1 and Type 2 Diabetes 30
    • 2.1.4 Signs and Symptoms 31
    • 2.1.5 Diabetes Monitoring 33
    • 2.1.6 Treatment 35
    • 2.1.7 Drug Delivery Systems 36

PROCEDURES 38

  • 3.1 PROCEDURE OVERVIEW 38
    • 3.1.1 Professional CGM Sensors Placed 38

ABBREVIATIONS 40

LIST OF CHARTS

  • Chart 1 1: Diabetes Monitoring, Treatment and Drug Delivery Market by Segment, U.S., 2013 - 2023 3
  • Chart 1 2: Diabetes Monitoring, Treatment and Drug Delivery Market Overview, U.S., 2013 &2023 3

LIST OF FIGURES

  • Figure 1 1: Diabetes Monitoring, Treatment and Drug Delivery Market Share Ranking by Segment, U.S., 2016 (1 of 2) 4
  • Figure 1 2: Diabetes Monitoring, Treatment and Drug Delivery Market Share Ranking by Segment, U.S., 2016 (2 of 2) 5
  • Figure 1 3: Companies Researched in this Report, U.S., 2016 6
  • Figure 1 4: Factors Impacting the Diabetes Monitoring, Treatment and Drug Delivery Market by Segment, U.S. (1 of 2) 7
  • Figure 1 5: Factors Impacting the Diabetes Monitoring, Treatment and Drug Delivery Market by Segment, U.S. (2 of 2) 8
  • Figure 1 6: Recent Events in the Diabetes Monitoring, Treatment and Drug Delivery Market, U.S., 2013 - 2016 9
  • Figure 1 7: Diabetes Monitoring, Treatment and Drug Delivery Markets Covered, U.S., 2016 10
  • Figure 1 8: Procedure Codes Investigated, U.S., 2016 10
  • Figure 1 9: Diabetes Monitoring, Treatment and Drug Delivery Markets Covered, U.S., 2016 (1 of 2) 11
  • Figure 1 10: Diabetes Monitoring, Treatment and Drug Delivery Markets Covered, U.S., 2016 (2 of 2) 12
  • Figure 1 11: Key Report Updates 13
  • Figure 1 12: Version History 13
  • Figure 2 1: Major Types of Diabetes and Related Pathologies, U.S., 2016 27
  • Figure 2 2: Risk Factors Associated with Type 1 and Type 2 Diabetes, U.S., 2016 31
  • Figure 2 3: Signs and Symptoms Associated with Type 1 and Type 2 Diabetes, U.S., 2016 32
Back to Top
아시아 최대 시장정보 제공
전세계에서 발행되고 있는 모든 시장조사보고서를
다루고 있습니다.
사이트에서 검색되지 않는 보고서도 문의 바랍니다.
 
BCC Research